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Abstract
This study examines the relationship between long-term intake of six ﬂavonoid classes and incidence of CVD and CHD, using a
comprehensive ﬂavonoid database and repeated measures of intake, while accounting for possible confounding by components of a healthy
dietary pattern. Flavonoid intakes were assessed using a FFQ among the Framingham Offspring Cohort at baseline and three times during
follow-up. Cox proportional hazards regression was used to characterise prospective associations between the natural logarithms of ﬂavonoid
intakes and CVD incidence using a time-dependent approach, in which intake data were updated at each examination to represent average
intakes from previous examinations. Mean baseline age was 54 years, and 45 % of the population was male. Over an average 14·9 years of
follow-up among 2880 participants, there were 518 CVD events and 261 CHD events. After multivariable adjustment, only ﬂavonol intake was
signiﬁcantly associated with lower risk of CVD incidence (hazard ratios (HR) per 2·5-fold ﬂavonol increase= 0·86, Ptrend= 0·05). Additional
adjustment for total fruit and vegetable intake and overall diet quality attenuated this observation (HR= 0·89, Ptrend= 0·20 and HR= 0·92,
Ptrend= 0·33, respectively). There were no signiﬁcant associations between ﬂavonoids and CHD incidence after multivariable adjustment. Our
ﬁndings suggest that the observed association between ﬂavonol intake and CVD risk may be a consequence of better overall diet. However,
the strength of this non-signiﬁcant association was also consistent with relative risks observed in previous meta-analyses, and therefore a
modest beneﬁt of ﬂavonol intake on CVD risk cannot be ruled out.
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In spite of many advances in the prevention and treatment of CVD
and corresponding declines in deaths attributed to CHD and
stroke, CVD remains the leading cause of death in the USA,
accounting for 31·9% of all deaths(1). An estimated 620 000
experience incident CHD events and 610 000 incident strokes each
year. Worldwide, it is estimated that there are more than seventeen
million deaths each year due to CVD, accounting for 30% of all
deaths, and CVD incidence continues to increase in low- and
middle-income countries where 80% of CVD deaths occur(2,3).
Diet has been shown to be a critical factor in CVD preven-
tion(4–6), and fruits and vegetables are an important part of diets
associated with lower CVD risk(7–10). However, the mechanism
relating vegetable and fruit intake to CVD risk is still uncertain.
Dietary ﬂavonoids – a class of polyphenols found in a large
array of plant foods – have been examined as potential com-
ponents associated with CVD risk. Previous studies have
examined the relationship between ﬂavonoid intakes and risk
for CVD(11), but many of these studies have one or more lim-
itations – for example, the earlier studies examined only a few
ﬂavonoid classes. Length of follow-up was often limited, and in
most cases with longer follow-up periods ﬂavonoid intakes
were based on a single baseline assessment, allowing the
potential for regression dilution bias(12,13). Finally, diets that are
high in ﬂavonoids are by their nature higher in fruits and
vegetables and are generally of higher diet quality, but many
studies did not account for possible confounding by overall diet
quality, fruit and vegetable intake, ﬁbre or other nutrients that
might track with ﬂavonoid intakes.
Therefore, we examined the relationship between incident
CVD and CHD and long-term intake for individual ﬂavonoid
classes based on a more complete ﬂavonoid database, and we
also measured intakes repeatedly during follow-up while
accounting for possible confounding by other components of a
healthy diet pattern.
* Corresponding author: P. F. Jacques, fax +1 617 556 3344, email paul.jacques@tufts.edu
Abbreviation: HR, hazard ratio.
British Journal of Nutrition (2015), 114, 1496–1503 doi:10.1017/S0007114515003141
© The Authors 2015. This is an Open Access article, distributed under the terms of the Creative
Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted
re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Methods
Population description
The Framingham Heart Study began in 1948 with the enrolment
of 5209 adults aged 28–62 years, residing in Framingham, a
town to the west of Boston, Massachusetts(14), and has con-
tinued for over 60 years, with the survivors returning every
2 years for a physical examination and to complete a series of
questionnaires as well as laboratory and cardiovascular tests. By
1971, the original cohort included 1644 husband–wife pairs and
378 individuals who had developed CVD. The offspring of
these subjects and the spouses of the offspring were invited to
participate, and 5135 of the 6838 eligible individuals partici-
pated in the ﬁrst Framingham Offspring Study examination(15).
The Offspring Cohort undergoes repeat examination approxi-
mately every 3–4 years. For the present study, we used data
derived from the ﬁfth, sixth, seventh and eighth study exam-
inations, which spanned 18 years (1991–2008), with follow-up
for incident CVD through 2008.
To be eligible for the present study, participants had to attend
the ﬁfth study examination (baseline for the present study) and
be free of CVD at baseline (n 3413). Of these eligible partici-
pants, we excluded 491 participants who were missing dietary
data at baseline or at two consecutive follow-up examinations
before the occurrence of a CVD event, censoring for other
reasons (e.g. non-CVD death) or the end of follow-up (eighth
examination). In addition, forty-two subjects were excluded
because of missing data on critical baseline covariates. The ﬁnal
sample for this study (N 2880) included 1302 men and
1578 women.
This study was conducted according to the guidelines laid
down in the Declaration of Helsinki, and all the procedures
involving human participants were approved by the Boston
University Medical Center Institutional Review Board. Written
informed consent was obtained from all the participants. The
present study was approved by the Tufts Medical Center Insti-
tutional Review Board.
Dietary assessment
Dietary intakes were assessed using a validated semi-quantitative
FFQ(16) at the ﬁfth, sixth, seventh and eighth examinations. The
FFQ consisted of a list of foods with a standard serving size and a
selection of nine frequency categories ranging from never or
<1 serving/month to ≥6 servings/d. Participants were asked to
report their frequency of consumption of each food item during
the past year. Participants could also add up to three additional
foods that are important components of their diets but were not
listed in the questionnaire. Information on nutrient supplement
use was also obtained by the FFQ. Dietary information was
judged as unreliable and excluded from further analysis if
reported total energy intakes were <2511 kJ/d (600 kcal/d)
or >16 743 kJ/d (4000 kcal/d) for women and >17 580 kJ/d
(4200 kcal/d) for men or if more than twelve food items were
left blank.
The ﬂavonoid database used for the FFQ was previously
described(17), and was primarily derived from the US Depart-
ment of Agriculture ﬂavonoid content of foods and the
proanthocyanidin databases(18,19). The same ﬂavonoid database
was used for all study examinations. We used the ﬂavonoid
classiﬁcation of Cassidy et al.(17) (Table 1) to deﬁne the six
ﬂavonoid classes. Total ﬂavonoids were deﬁned as the sum of
all six classes. We did not evaluate isoﬂavone intakes because
habitual intakes are very low in the US diet(20–23).
The validity of ﬂavonoid intake from the Harvard FFQ has not
been directly assessed, but the validity for the food intake based
on a comparison of the FFQ and two 7 d diet records collected
during the year time interval covered by the FFQ has previously
been published(24). This comparison demonstrated relatively
high correlation coefﬁcients between intakes from the FFQ and
diet records for the major dietary sources of ﬂavonoids in the
Framingham Offspring Cohort, including apples/pears (0·70),
bananas (0·95), oranges (0·76), orange juice (0·78), strawberries
(0·38), mufﬁns (0·66), tea (0·77) and red wine (0·83).
Ascertainment of CVD events and deaths
All the participants are under continuous surveillance for the
occurrence of CVD events and death. Hospitalisation records
and physician ofﬁce visit records are obtained and reviewed by
a committee of three experienced investigators. For each death,
the same committee assigns an underlying cause of death based
on Framingham Heart Study records, hospitalisation records
and, when available, autopsy results(25). Criteria for the diag-
noses of cardiovascular events have been described else-
where(26). Incident CVD includes CHD (recognised or
unrecognised myocardial infarction, angina pectoris, coronary
insufﬁciency and CHD death), cerebrovascular disease (stroke
and transient ischaemic attack), congestive heart failure (by
Framingham criteria) and peripheral vascular disease (inter-
mittent claudication). An unrecognised myocardial infarction
was considered to have occurred if there was electrocardio-
graphic evidence of signiﬁcant loss of R waves or appearance of
pathologic Q waves on serial tracings in the absence of a
clinically recognised event. Sudden death, deﬁned as death
occurring within 1 h of onset of symptoms, was attributed to
CHD, unless another cause was apparent(25). Stroke was
deﬁned as an acute-onset focal neurological deﬁcit of presumed
vascular origin persisting for ≥24 h. Transient ischaemic attack
was deﬁned as an episode of rapid-onset focal neurological
dysfunction attributed to focal cerebral ischaemia with resolu-
tion within 24 h. All cerebrovascular events were adjudicated by
Table 1. Definition of flavonoid subclasses
Flavonoid subclass Flavonoid compounds
Flavonols Quercetin, kaempferol, myricetin, isorhamnetin
Flavones Luteolin, apigenin
Flavanones Eriodictyol, hesperetin, naringenin
Flavan-3-ols Catechin, gallocatechin, epicatechin,
epigallocatechin, epicatechin 3-gallate,
epigallocatchin 3-gallate
Anthocyanidins Cyanidin, delphinidin, malvidin, pelargonidin,
petunidin, peonidin
Polymeric flavonoids Proanthocyanidins (dimers, trimers, 4–6-mers,
7–10-mers, polymers, excluding monomers),
theaflavins, thearubigins
Flavonols and CVD incidence 1497
a panel of two neurologists(27). For intermittent claudication, a
physician-administered standardised questionnaire was used to
elicit subjective symptoms of calf discomfort with exertion that
occurred sooner with uphill or fast-paced walking and was
alleviated with rest. All suspected claudication events were
veriﬁed independently by a second physician examiner.
Assessment of covariates
The covariates used in our analyses as potential confounders
included sex, age, current smoking status, BMI, waist
circumference, total energy intake, fruit and vegetable intake,
overall diet quality, alcohol intake, hypertension, prevalent
diabetes and cholesterol-lowering drug use. Medical history
(e.g. medication use) and lifestyle activities (e.g. smoking history)
were assessed during a standardised medical examination and
interview. Waist circumference was measured at the level
of the umbilicus at standing position. Height and weight were
measured with the participant standing, with their shoes off and
wearing only a hospital gown. BMI was calculated as body
weight in kilograms divided by the square of height in metres.
Alcohol intake was derived from the FFQ. Sitting blood pressure
was measured twice for each participant after a 5 min rest
using a random-zero sphygmomanometer, and the two read-
ings were averaged for the analyses. Diabetes was deﬁned as a
plasma glucose level ≥7·0mmol/l (fasting) or ≥11·1 mmol/l
(non-fasting) or use of hypoglycaemic drug therapy. Overall
dietary quality was assessed using the 2010 Dietary Guidelines
for Americans Adherence Index (DGAI)(28). The DGAI is a
twenty-item score designed as a measure of adherence to the
key recommendations from the 2005 Dietary Guidelines for
Americans.
Statistical methods
We used a time-dependent approach for the statistical analyses
in which ﬂavonoid intake data was updated at each examina-
tion as the cumulative mean of intakes from the current and all
previous examinations – for example, events at the sixth
examination were related to the mean of the intakes at the ﬁfth
and sixth examinations, events at the seventh examination were
related to the mean of the intakes from the ﬁfth, sixth and
seventh examinations, etc. If participants were missing intake
data at one of the follow-up examinations, the mean intake was
based on the available intake data. Those who had data missing
at baseline or two consecutive follow-up examinations before
the development of an incident CVD event or the end of follow-
up were excluded from the analyses. The natural logarithms of
the different ﬂavonoid class intakes were used as the exposure
variables to account for non-linear relations with the outcomes
total CVD and CHD incidence. We were substantially
underpowered to consider stroke as a separate outcome (n 83).
The time-dependent covariates (current smoking status, BMI,
cholesterol-lowering medication use, diabetes and hyperten-
sion) were updated at each examination, and dietary covariates
were updated as cumulative averages as we did for the
ﬂavonoid intakes. If covariates were missing at follow-up, they
were carried forward from the previous examination.
Hazard ratios (HR) derived from Cox proportional hazards
regression models (SAS PROC PHREG) were used to char-
acterise the prospective associations between ﬂavonoid intakes
and incidence of CVD and CHD. As ﬂavonoid intakes were
transformed using a natural logarithm, the HR represents the
relative risk for a proportional difference in ﬂavonoid intake.
We presented HR for a 2·5-fold difference in ﬂavonoid intake,
which approximated the smallest relative difference between
the 75th and 25th percentile values for intake of the individual
ﬂavonoid classes across study examinations (Table 2).
For our analyses, we considered the following ﬁve different
models: (1) an age- and sex-adjusted model (model 1); (2) a
multivariable model including model 1 with additional adjust-
ment for current smoking status, BMI and total energy intake
(model 2); (3) model 2 with additional adjustment for fruit and
vegetable intakes; (4) model 2 with additional adjustment for
alcohol consumption; and (5) model 2 with additional adjust-
ment for clinical covariates including waist circumference,
hypertension, diabetes and cholesterol-lowering drug use. We
also considered a model including variables in model 2 with
additional adjustment for overall diet quality using the DGAI;
however, given that the results were similar to the model with
adjustment for fruit and vegetable intakes and the sample size
available for the DGAI score was smaller due to missing data,
we did not include our ﬁndings based on this model in our
tables, but reported relevant ﬁndings in the text.
To examine the relationship between the top food sources of
the speciﬁc ﬂavonoid classes inversely associated with CVD, we
identiﬁed all foods that contributed at least 10 % of the intake of
each ﬂavonoid class and related the intake of these foods to
CVD incidence. We classiﬁed food intake into three categories,
which were equivalent (<1 serving/week, 1–4 servings/week
and ≥5 servings/week) and applied the same proportional
hazards regression analysis approach that was described above
for the ﬂavonoids. A test for trend across food serving categories
was based on assigning the median servings in each category to
individuals in that category and treating that resulting variable
as a continuous variable in the regression models.
To assess the validity of the proportional hazards assumption,
we introduced interaction terms between follow-up time and our
exposures, and we used likelihood ratio tests to assess evidence
Table 2. Flavonoid intake of members of the Framingham Heart Study
Offspring Cohort at the fifth and eighth examinations
(Medians and 25th, 75th percentiles; n 2880)
Exam 5
(1991–1995)
Exam 8
(2005–2008)
Flavonoid class Median
25th, 75th
percentiles Median
25th, 75th
percentiles
Flavonols (mg/d) 10·6 6·7, 16·5 11·7 7·5, 17·5
Flavones (mg/d) 1·6 0·8, 2·6 1·7 0·9, 2·7
Flavanones (mg/d) 35·1 11·0, 62·1 25·7 8·2, 57
Flavan-3-ols (mg/d) 21·7 11·8, 50·1 27·2 14·0, 59·5
Anthocyanins (mg/d) 9·1 3·4, 17·3 17·8 8·1, 29·2
Polymeric flavonoids (mg/d) 114 59, 226 156 86, 280
Total flavonoids* (mg/d) 212 124, 372 259 157, 436
* Total flavonoid intakes exclude isoflavones, which were not measured in this study.
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for departures from this assumption. There was no evidence that
this assumption was violated for any of our models. We also
performed a sensitivity analysis excluding CVD and CHD cases
that occurred within the ﬁrst 2 years of follow-up.
All the analyses were performed using SAS version 9.2 (SAS
Institute). A P value <0·05 was considered statistically signiﬁcant.
Results
Median total ﬂavonoid intakes (excluding isoﬂavones) increased
modestly across follow-up from 212mg/d at the ﬁfth Framing-
ham Offspring Study examination (1991–1995) to 259mg/d at
the eighth study examination (2005–2008) (Table 2). This
increase was in large part due to higher intakes of polymeric
ﬂavonoids, which comprised more than half of the total ﬂavo-
noids. Median anthocyanin intake also nearly doubled over this
time period from 9·1 to 17·8mg/d. There was substantial varia-
tion in intakes among participants as demonstrated by the
interquartile ranges (75th–25th percentile values) of the total
ﬂavonoids and the ﬂavonoid classes. In all cases, except for
ﬂavonol intake, the 75th percentile values were more than three
times greater than the 25th percentile values, ranging to more
than ﬁve to seven times higher for ﬂavanones. For ﬂavonols, the
relative difference between the 75th and 25th percentiles was 2·5
at the ﬁfth examination and 2·3 at the eighth examination.
Over an average of 14·9 years of follow-up (range 1 month–
19·9 years), there were 518 incident CVD events, including 261
CHD events (112 myocardial infarctions, 102 angina pectoris,
twenty CHD deaths, thirteen coronary insufﬁciency and four-
teen unspeciﬁed), eighty-three strokes, forty-seven transient
ischaemic attacks, seventy-nine congestive heart failure events,
forty-four peripheral vascular disease events and four other/
unspeciﬁed CVD events. Individuals with the highest total ﬂa-
vonoid intakes were more likely to be women and less likely to
be smokers and to have lower BMI, higher energy, fruit and
vegetable intakes and a better overall diet quality (Table 3).
Prevalence of diabetes and hypertension and use of medica-
tions for hypercholesterolaemia, hypertension and diabetes
were unrelated to ﬂavonoid intake.
We observed that intakes of total ﬂavonoids and all ﬂavonoid
classes, except for ﬂavones and ﬂavanones, were inversely
associated with CVD incidence after adjusting for age and sex
(Table 4). After additional adjustment for smoking, BMI and
total energy intake, only ﬂavonol intake remained signiﬁcantly
inversely associated with CVD incidence. Addition of waist
circumference, hypertension, diabetes and cholesterol-lowering
drug use to the previous model did not materially affect the
association between ﬂavonol and CVD incidence (HR= 0·86,
95 % conﬁdence limits (CL) 0·74, 1·01, Ptrend= 0·06) and
additional adjustment for alcohol intake modestly strengthened
the association (HR= 0·81, 95 % CL 0·68, 0·95, Ptrend= 0·01).
However, additional adjusting for fruit and vegetable intakes
attenuated this relationship (Table 4). Additional adjustment for
overall diet quality also attenuated the relationship (HR= 0·92,
95 % CL 0·78, 1·09, Ptrend= 0·33).
Although in many cases the HR for the associations between
ﬂavonoid intakes and CHD incidence were similar to those for
CVD incidence, only the inverse association between ﬂavone Ta
b
le
3.
P
ar
tic
ip
an
t
ch
ar
ac
te
ris
tic
s*
by
qu
ar
til
e
ca
te
go
rie
s
of
to
ta
lf
la
vo
no
id
in
ta
ke
(M
ea
n
va
lu
es
an
d
95
%
co
nf
id
en
ce
lim
its
(C
L)
;
or
pe
rc
en
ta
ge
s)
O
ve
ra
ll
(n
28
80
)
Q
ua
rt
ile
1
(n
72
0)
Q
ua
rt
ile
2
(n
72
0)
Q
ua
rt
ile
3
(n
72
0)
Q
ua
rt
ile
4
(n
72
0)
P
ar
tic
ip
an
t
ch
ar
ac
te
ris
tic
s
M
ea
n
95
%
C
L
M
ea
n
95
%
C
L
M
ea
n
95
%
C
L
M
ea
n
95
%
C
L
M
ea
n
95
%
C
L
P
M
al
e
(%
)
45
·2
43
·4
,
47
49
·7
46
·1
,
53
·4
49
·4
45
·8
,
53
·1
47
·2
43
·6
,
50
·8
34
·4
30
·8
,
38
<
0·
00
1
A
ge
(y
ea
rs
)
54
·2
53
·8
,
54
·5
53
·4
52
·7
,
54
·1
54
·3
53
·6
,
55
54
·4
53
·7
,
55
·1
54
·7
54
,
55
·4
0·
04
B
M
I
(k
g/
m
2
)†
26
·9
26
·7
,
27
·0
27
·4
27
·1
,
27
·8
27
·1
26
·8
,
27
·5
26
·7
26
·3
,
27
·0
26
·3
26
·0
,
26
·6
<
0·
00
1
C
ur
re
nt
sm
ok
er
(%
)
18
·3
16
·9
,
19
·7
29
·4
26
·6
,
32
·2
17
·3
14
·5
,
20
·1
12
·9
10
·1
,
15
·7
13
·8
11
,
16
·5
<
0·
00
1
D
ia
be
te
s
(%
)
6·
0
5·
1,
6·
9
6·
7
5,
8·
5
5
3·
2,
6·
7
7
5·
2,
8·
7
5·
4
3·
7,
7·
1
0·
55
H
yp
er
te
ns
io
n
(%
)
19
·5
18
·2
,
20
·9
19
·7
16
·9
,
22
·5
19
·9
17
·1
,
22
·7
20
·3
17
·5
,
23
·1
18
·3
15
·5
,
21
·1
0·
42
M
ed
ic
at
io
n
us
e
C
ho
le
st
er
ol
-lo
w
er
in
g
(%
)
5·
3
4·
5,
6·
1
5·
2
3·
6,
6·
8
4·
8
3·
2,
6·
4
6·
3
4·
7,
7·
9
4·
9
3·
3,
6·
6
0·
96
A
nt
i-d
ia
be
tic
(%
)
2·
5
2,
3·
1
2·
8
1·
7,
4
2·
1
1,
3·
3
2·
4
1·
3,
3·
6
2·
7
1·
6,
3·
9
0·
87
H
yp
er
te
ns
io
n
(%
)
16
·7
15
·4
,
18
17
14
·4
,
19
·6
17
·2
14
·6
,
19
·8
18
15
·4
,
20
·6
14
·6
12
,
17
·3
0·
16
A
ny
at
ba
se
lin
e
(%
)‡
19
·7
18
·3
,
21
·1
19
·9
17
·1
,
22
·7
19
·5
16
·8
,
22
·3
21
·7
18
·9
,
24
·5
17
·6
14
·8
,
20
·4
0·
26
A
ny
at
fo
llo
w
-u
p
(%
)‡
58
·1
56
·4
,
59
·8
58
·6
55
·2
,
62
·1
58
·9
55
·5
,
62
·3
58
·9
55
·5
,
62
·3
55
·9
52
·4
,
59
·4
0·
21
E
ne
rg
y
(k
J/
d)
†
74
76
·8
73
88
·9
,
75
64
·7
61
46
·3
60
08
·2
,
62
84
·4
73
55
·5
71
92
·3
,
75
18
·6
80
08
·2
78
32
·4
,
81
88
·1
86
31
·6
84
39
·1
,
88
24
·1
<
0·
00
1
E
ne
rg
y
(k
ca
l/d
)†
17
87
17
66
,
18
08
14
69
14
36
,
15
02
17
58
17
19
,
17
97
19
14
18
72
,
19
57
20
63
20
17
,
21
09
<
0·
00
1
Fr
ui
t
in
ta
ke
(g
)§
25
6
24
9,
26
3
12
8
12
0,
13
7
24
4
23
3,
25
6
33
6
32
3,
35
0
35
0
33
6,
36
5
<
0·
00
1
V
eg
et
ab
le
in
ta
ke
(g
)§
25
5
25
1,
26
0
22
4
21
6,
23
3
24
9
24
0,
25
7
27
3
26
4,
28
2
27
8
26
9,
28
7
<
0·
00
1
D
ie
t
qu
al
ity
(D
G
A
I)
58
·4
58
,
58
·8
52
51
·3
,
52
·7
58
57
·3
,
58
·7
61
·8
61
·1
,
62
·5
61
·8
61
·1
,
62
·5
<
0·
00
1
D
G
A
I,
D
ie
ta
ry
G
ui
de
lin
es
fo
r
A
m
er
ic
an
s
A
dh
er
en
ce
In
de
x.
*
C
ha
ra
ct
er
is
tic
s
as
m
ea
su
re
d
at
ba
se
lin
e,
ex
ce
pt
as
no
te
d.
†
G
eo
m
et
ric
m
ea
ns
.
‡
Li
pi
d-
lo
w
er
in
g,
an
ti-
di
ab
et
ic
or
bl
oo
d
pr
es
su
re
-lo
w
er
in
g
m
ed
ic
at
io
n
us
e
at
ba
se
lin
e
an
d
at
th
e
la
st
fo
llo
w
-u
p
vi
si
t
fo
r
ea
ch
pa
rt
ic
ip
an
t.
§
S
qu
ar
e
ro
ot
tr
an
sf
or
m
at
io
n,
ba
ck
tr
an
sf
or
m
ed
to
or
ig
in
al
un
its
.
Flavonols and CVD incidence 1499
intake and CHD incidence was statistically signiﬁcant in the
age- and sex-adjusted models, but was not statistically
signiﬁcant after adjusting for current smoking, BMI and total
energy intake (Table 5). Addition of waist circumference,
hypertension, diabetes and cholesterol-lowering drug use,
alcohol intake or fruit and vegetable intakes to the previous
model did not affect any of the associations between the
ﬂavonoids and CHD risk (data not shown).
We performed sensitivity analyses excluding thirty-three
incident cases of CVD and twenty-two incident cases of CHD
that occurred within the ﬁrst 2 years of follow-up. Findings from
these analyses were similar to the complete analyses, and
therefore the results are not presented.
As ﬂavonol intake remained signiﬁcantly associated with
CVD incidence after multivariable adjustment, we examined
CVD incidence by intake categories of the top food sources of
ﬂavonols (Table 6). Tea and apples/pears were the only indi-
vidual food items that contributed at least 10 % of total ﬂavonol
intake and together comprised approximately 31 % of ﬂavonol
intake at the ﬁfth Offspring examination. Although both tea and
apple/pear consumption were inversely associated with CVD
incidence after adjusting for age and sex, both associations
were attenuated after multivariable adjustment. The association
with tea remained marginally signiﬁcant (Ptrend= 0·07).
Discussion
Our ﬁndings, based on long-term follow-up of middle-aged and
older Americans, suggest a possible beneﬁt of a higher ﬂavonol
intake on risk of CVD, but this may in part be due to differences
in dietary patterns among those consuming the highest amounts
of ﬂavonols, such as higher fruit and vegetable intake. Existing
evidence regarding ﬂavonoid intake and CVD risk remains
largely equivocal(11). Two recent meta-analyses from the same
research group including ﬁfteen prospective studies (repre-
senting eleven unique cohorts, fourteen in a meta-analysis of
Table 4. Relative risk (RR)of total CVD events over 20 years of follow-up* for each 2·5-fold increase in daily flavonoid intake
(Relative risks and 95% confidence limits (CL))
Age and sex adjusted Multivariable adjusted† Multivariable + fruit/vegetable
Flavonoid class RR 95% CL P RR 95% CL P RR 95% CL P
Flavonols 0·79 0·69, 0·91 0·001 0·86 0·74, 1·00 0·05 0·89 0·75, 1·06 0·20
Flavones 0·87 0·76, 1·00 0·06 0·98 0·84, 1·13 0·74 1·00 0·82, 1·21 0·99
Flavanones 0·95 0·89, 1·02 0·13 1·00 0·93, 1·07 0·98 1·00 0·92, 1·09 0·97
Flavan-3-ols 0·91 0·83, 0·98 0·02 0·95 0·88, 1·04 0·29 0·97 0·88, 1·05 0·43
Anthocyanins 0·89 0·82, 0·97 0·006 0·94 0·86, 1·02 0·14 0·95 0·86, 1·05 0·30
Polymeric flavonoids 0·87 0·80, 0·95 0·002 0·92 0·84, 1·01 0·08 0·93 0·84, 1·02 0·13
Total flavonoids 0·86 0·77, 0·95 0·004 0·93 0·83, 1·04 0·20 0·93 0·82, 1·06 0·26
* Mean follow-up time of 14·9 years; n 518 CVD events.
† Multivariable model adjusted for age (years), sex, current smoking status (yes/no), BMI (kg/m2) and total energy intake (kJ/d (kcal/d)).
Table 5. Relative risk (RR) of CHD events over 20 years of follow-up* for each 2·5-fold increase in daily flavonoid intake
(Relative risks and 95% confidence limits (CL))
Age and sex adjusted Multivariable adjusted† Multivariable+ fruit/vegetable
Flavonoid class RR 95% CL P RR 95% CL P RR 95% CL P
Flavonols 0·84 0·69, 1·02 0·08 0·90 0·73, 1·12 0·36 0·96 0·76, 1·22 0·76
Flavones 0·80 0·66, 0·97 0·03 0·87 0·71, 1·07 0·19 0·83 0·64, 1·09 0·18
Flavanones 0·92 0·84, 1·01 0·09 0·96 0·87, 1·06 0·40 0·94 0·85, 1·06 0·32
Flavan-3-ols 0·95 0·84, 1·07 0·38 1·00 0·88, 1·13 0·97 1·01 0·89, 1·14 0·86
Anthocyanins 0·92 0·82, 1·03 0·14 0·96 0·85, 1·08 0·49 0·98 0·86, 1·12 0·76
Polymeric flavonoids 0·91 0·8, 1·03 0·13 0·96 0·84, 1·10 0·53 0·97 0·84, 1·12 0·68
Total flavonoids 0·88 0·76, 1·02 0·10 0·95 0·81, 1·11 0·51 0·96 0·80, 1·14 0·63
* Mean follow-up time of 14·9 years; n 261 CHD events.
† Multivariable model adjusted for age (years), sex, current smoking status (yes/no), BMI (kg/m2) and total energy intake (kJ/d (kcal/d)).
Table 6. Relation of cumulative food intake and total CVD events over 20
years of follow-up* for the Framingham Heart Study Offspring Cohort
(Hazard ratios (HR) and 95% confidence limits (CL))
Age and sex adjusted Multivariable adjusted†
Food (amount/week)‡ HR 95% CL P HR 95% CL P
Tea (ml)
<237 1 1
237–948 0·91 0·75, 1·10 0·34 1·00 0·82, 1·21 0·98
1185+ 0·71 0·55, 0·92 0·01 0·78 0·60, 1·01 0·07
Ptrend 0·01 0·07
Apples/pears (g)
<138 1 1
138–118 0·75 0·58, 0·97 0·03 0·82 0·63, 1·06 0·14
148+ 0·62 0·42, 0·91 0·02 0·74 0·50, 1·10 0·14
Ptrend 0·03 0·16
* Mean follow-up time of 14·9 years; n 518 CVD events.
† Multivariable model adjusted for age (years), sex, current smoking status (yes/no),
BMI (kg/m2) and total energy intake (kJ/d (kcal/d)).
‡ The categories of food intake amounts are equivalent to <1 serving/week, 1–4
servings/week and ≥5 servings/week, respectively, with one serving defined as 8 fl.
oz. of tea and one medium apple or pear.
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CVD events(29) and eight in a meta-analysis of stroke events(30))
concluded that dietary intakes of all six ﬂavonoid classes were
associated with lower risks of CVD and ﬂavonol intake was
associated with a lower stroke risk in men.
However, many of the existing concerns with the previous
epidemiological studies, such as inclusion of all classes in the
ﬂavonoid databases, the possible confounding by diet quality
and the use of a single baseline estimate of intake, are not
addressed in these meta-analyses(29,30). For example, eleven of
these ﬁfteen studies used older ﬂavonoid databases that
included only a few ﬂavonoid classes. Four of these studies
considered only one class of ﬂavonoids(31–34) and seven
considered only two to three classes(35–41).
None of these ﬁfteen studies considered confounding by
overall diet quality, three considered possible confounding
by a single dietary factor that may be higher in ﬂavonoid-
containing foods such as dietary ﬁbre or vitamin C(31–33), and
only one study considered potential confounding by fruit and
vegetable intake(40). Mink et al.(42) included the most complete
adjustment of dietary factors (indirectly addressing overall diet
quality), including intakes of whole grains, ﬁsh and seafood,
folate, vitamin C, β–carotene and fatty acids in their analyses.
The longer length of follow-up and assessment of diet only at
baseline combine to increase the probability of regression
dilution bias, which results from misclassiﬁcation of exposure
using only baseline values(12,13). Regression dilution bias results
in the attenuation of the true association. To prevent such bias,
replicate measures are needed during follow-up. Only two of
these studies collected replicate measures of ﬂavonoid intakes
during follow-up(41,43). Of the thirteen that relied only on
baseline assessment to characterise ﬂavonoid intakes(31–40,42,44,45),
the average follow-up time was 10·8 years, allowing ample time
for variation in ﬂavonoid intakes.
Potential limitations for the existing studies described above
will not similarly explain a lack of association resulting from
bias or the existence of an apparent association due to bias. For
example, given that ﬂavonoids are found in plant-based foods,
the overall diet quality of higher ﬂavonoid consumers is likely to
be better than those consuming lower amounts of ﬂavonoids, as
we have shown in the present study. Foods containing greater
amounts of ﬂavonoids tend to be good sources of nutrients
(such as K, Mg, ﬁbre and lignans) that might reduce CVD risk
and lower in other nutrients (such as SFA and Na) that may
increase CVD risk. Consequently, failure to account for poten-
tial confounding by overall dietary quality or other speciﬁc
dietary factors that may be associated with ﬂavonoid intakes
would be a likely cause of false-positive associations. The use of
incomplete ﬂavonoid databases and the combination of long
follow-up periods without accounting for possible changes in
exposure, on the other hand, would be more likely to diminish
the strength of any true associations resulting in false-negative
associations. Consequently, these sources of potential bias
would not likely be responsible for the observed associations
between ﬂavonoids and CVD risk summarised in the
aforementioned meta-analyses(29,30).
When we attempted to address these limitations in the
present study, the only observation that remained statistically
signiﬁcant after adjusting for age, sex, BMI, current smoking and
total energy intake was the inverse relationship between
ﬂavonol intakes and CVD. This association was attenuated and
no longer statistically signiﬁcant after further adjustment for fruit
and vegetable consumption or overall diet quality, suggesting
that this relation was due, at least in part, to better diets con-
sumed by individuals with higher ﬂavonol intakes. However,
even after adjusting for fruits and vegetables, the observed
relative risk was 0·89, which was identical to the overall relative
risk (0·89, 95 % CL 0·84, 0·94) reported by Wang et al.(29) in their
meta-analysis of ﬂavonols and CVD risk.
Several mechanisms have been proposed by which ﬂavonols
might inﬂuence CVD risk, including effects on endothelium and
vascular smooth muscle, platelet function, blood pressure,
inﬂammation, body weight and composition, and insulin
resistance(46,47). Flavonols are widely distributed in plant
products. In the Framingham Offspring Cohort, we have
previously show that the major sources of dietary ﬂavonols
were tea, apples and pears, together constituting about 31 % of
ﬂavonol intake(48). We observed that CVD incidence was
inversely associated with consumption of both tea and apples
and pears, but these associations were attenuated and no longer
statistically signiﬁcant after additional adjustments for smoking,
BMI and total energy intake. However, even the attenuated HR
indicated a >20 % lower CVD risk for the highest consumers of
both of these food items.
We had previously observed associations between ﬂavonol
and ﬂavan-3-ol intakes and type 2 diabetes, an important CVD
risk factor(48). Consequently, the weak association between
ﬂavonol and CVD and the absence of an association between
ﬂavan-3-ols, with or without accounting for type 2 diabetes in
this population, is puzzling. As a part of the longest longitudinal
study of CVD development in the USA, the Framingham Off-
spring Cohort and their healthcare providers may be uniquely
attuned to CVD risk. It is possible that the large proportion of
the population on medications for CVD risk factors (including
antihypertensive, cholesterol lowering and diabetes medica-
tions) may have limited our ability to detect any association
with ﬂavonoids. Although the use of these medications was
relatively low at baseline, 58 % of the participants were taking
one or more of these medications by the end of their follow-up.
The use of medications may have effects on disease risk that are
stronger than dietary inﬂuences and may have diminished the
ability to detect associations between dietary factors and
CVD risk.
The usual doses of ﬂavonoids used in intervention studies
examining their effects on CVD risk factors tend to be many
times greater than the intakes of ﬂavonoids in most populations.
For ﬂavonols, the intervention doses are usually at least ten
times greater(49) than those seen in the Framingham Offspring
Cohort. The non-linear nature of the relationship we observed
between ﬂavonol intake and CVD risk suggest that beneﬁts may
be achieved with lower doses over a longer time period. Our
models suggest that the beneﬁt of increasing ﬂavonol dose on
CVD risk diminishes in an exponential manner, with most of the
beneﬁt obtained by modest increases among individuals with
the lowest intakes. For example, a 2·5-fold difference in intake
from about 4 to 10mg/d (or change of 6 mg/d) is associated
with a 14 % reduction in CVD risk in our multivariable model,
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whereas a similar reduction in risk would be seen for a 30 mg/d
difference for those with intakes of 20 mg/d.
Our study accounted for many limitations of earlier studies –
for example, we used more complete ﬂavonoid databases, our
analyses accounted for overall dietary quality and intake of
important sources of ﬂavonoids (fruits and vegetables) and we
used multiple assessments of ﬂavonoid intake collected during
follow-up. However, this work still has several limitations. We
used the Harvard FFQ to assess ﬂavonoid intake, which may
not have captured intakes of some of the richer, but less fre-
quently consumed, sources of ﬂavonoids, such as cranberries,
spices (dill, thyme, mint), nuts (pecans, walnuts), beans (black,
kidney, fava). However, the Harvard FFQ does well for many of
the most frequently consumed ﬂavonoid sources(24) including
apples, bananas, oranges and orange juice, tea and red wine.
Another limitation is that the most recent version of the USDA
Database for the Flavonoid Content of Selected Foods(50) had
not been incorporated into the Harvard FFQ database at the
time we performed our analyses. In addition, we recognise that
the chemical analyses currently available for assessing thear-
ubigin intakes represent only a rather crude estimate; however,
for completeness, we wanted to include all available ﬂavonoid
intake data(51). Although CHD accounted for more than one-
half of all incident CVD events, we did not see any statistically
signiﬁcant associations after multivariable adjustment. This may
be in part due to the lower power of the CHD analyses, as the
relative risks, although NS, were consistent in magnitude with
many of those reported in the earlier meta-analysis for overall
CVD(29). We also had insufﬁcient power to examine the asso-
ciations with stroke incidence in this population. The members
of the Framingham Offspring Cohort are largely Caucasians of
Northern European descent, and they and their healthcare
providers are likely to be highly conscious of cardiovascular risk
factors, and thus generalisations to other populations may be
limited. Finally, we did not adjust for multiple testing because of
hypothesised relations based on existing evidence.
In summary, the role that ﬂavonoids may play in prevention of
CVD remains uncertain. Our ﬁndings provide limited support for
a beneﬁcial relationship between a higher intake of ﬂavonols
and CVD incidence, but for none of the other ﬂavonoid classes
commonly consumed in the US diet. In spite of continuing
improvements in the ﬂavonoid databases and our dietary
assessment tools, there is still a large amount of imprecision in
our estimates of ﬂavonoid intakes that limit our ability to deter-
mine their role in CVD and other health outcomes. Many
methodological issues need to be addressed to allow us to more
adequately examine these associations(52). In the meantime,
animal experiments and clinical intervention trials with validated
surrogate outcomes of CVD will be essential to complement the
limitations of the evidence from observational studies.
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